News - Genzyme

Filter

Current filters:

Genzyme

Popular Filters

46 to 70 of 70 results

Isis earns $25 million milestone from Genzyme as US FDA accepts Kynamro NDA

31-05-2012

The US Food and Drug Administration has accepted for filing the New Drug Application for Kynamro (mipomersen…

BiotechnologyCardio-vascularFinancialGenzymeIsis PharmaceuticalsKynamroNorth AmericaPharmaceuticalRegulationSanofi

Elelyso: a new therapeutic option for patients with Gaucher disease

09-05-2012

The US Food and Drug Administration recently approved Protalix BioTherapeutic's (NYSE-AMEX: OLX) Elelyso…

CerezymeElelysoGenzymeMarkets & MarketingPfizerPharmaceuticalProtalix BioTherapeuticsRare diseasesShireVpriv

Genzyme gains FDA and EMA approval for Irish production plant

03-05-2012

US biotech firm Genzyme, a subsidiary of French drug major Sanofi (Euronext: SAN) said yesterday that…

BiotechnologyEuropeGenzymeLumizymeMyozymeRegulationSanofi

Sanofi's strong 1st-qtr driven by Genzyme

27-04-2012

French drug major Sanofi (Euronext: SAN) posted a strong set of first-quarter 2012 financial results…

BiotechnologyFinancialGenzymePharmaceuticalSanofi

Genzyme and Isis file Kynamro NDA in USA

02-04-2012

Biotech firm Genzyme, a subsidiary of French drug major Sanofi (Euronext: SAN), has submitted a New Drug…

Cardio-vascularGenzymeIsis PharmaceuticalsKynamroNorth AmericaPharmaceuticalRare diseasesRegulationSanofi

Genzyme to start shipping Fabrazyme from newly-approved plant

01-03-2012

French drug major Sanofi's (Euronext: SAN) US subsidiary Genzyme says that it has begun shipping its…

BiotechnologyFabrazymeGenzymeMarkets & MarketingPharmaceuticalRare diseasesSanofi

GSK inks $300m rare diseases alliance with Angiochem

28-02-2012

GlaxoSmithKline has forged an R&D alliance with Montreal, Canada-based Angiochem that will focus on the…

AngiochemCerezymeGenzymeGSKNeurologicalPharmaceuticalRare diseasesShireVpriv

Sanofi surprises Osiris by pulling out of Prochymal deal

13-02-2012

Maryland, USA-based Osiris Therapeutics (Nasdaq: OSIR) has provided an update on the status of the development…

GenzymeImmunologicalsLicensingOsiris TherapeuticsPharmaceuticalProchymalSanofi

Positive Ph II results for Genzyme’s oral Gaucher drug

09-02-2012

French drug major Sanofi’s (Euronext: SAN) US subsidiary Genzyme yesterday revealed four-year follow-up…

BiotechnologyeliglustatGenzymePharmaceuticalRare diseasesResearchSanofi

Genzyme Framingham plant now cleared by US and EU regulators

24-01-2012

French drug major Sanofi (Euronext: SAN) said yesterday that the US Food and Drug Administration has…

BiotechnologyFabrazymeGenzymePharmaceuticalRare diseasesRegulationSanofi

Isis sees Kynamro delay; adds new drugs to pipeline

15-12-2011

California, USA-based Isis Pharmaceuticals (Nasdaq: ISIS) announced yesterday that there will be a slight…

Cardio-vascularGenzymeIsis PharmaceuticalsKynamromipomersenNephrology and HepatologyPharmaceuticalRegulationResearchSanofi

Genzyme’s MS drug Lemtrada shows significant efficacy versus Rebif

15-11-2011

US biotech firm Genzyme, a subsidiary of French drug major Sanofi (Euronext: SAN) says that the Phase…

BayerGenzymeLemtradaNeurologicalPharmaceuticalRebifResearchSanofi

Sanofi 3rd-qtr 2011 net profit falls 3%, hit by generic competition

03-11-2011

Sanofi’s (Euronext: SAN) group sales for the third quarter of 2011 came in at 8.75 billion euros…

FinancialGenzymePharmaceuticalSanofi

Sanofi names David Meeker as chief executive of Genzyme; Exelixis hires former Genentech exec

25-10-2011

French drug major Sanofi (Euronext: SAN) has appointed David Meeker as chief executive of its USA-based…

BiotechnologycabozantinibExelixisGenzymeManagementPharmaceuticalSanofi

Ongoing supply problems for Genzyme’s Cerezyme

19-09-2011

US biotech Genzyme, now a subsidiary of French drug major Sanofi (Euronext: SAN), says it will have only…

BiotechnologyCerezymeFabrazymeGenzymeMarkets & MarketingPharmaceuticalRare diseasesSanofiShire

Sanofi sets 5% sales growth goal; views Genzyme synergies, patent losses and R&D

07-09-2011

Christopher Viehbacher, chief executive of French drug major Sanofi (Euronext: SAN), says the company…

FinancialGenzymePharmaceuticalResearchSanofi

NIH scientists repurpose Genzyme’s FDA-approved plerixafor for rare disease

05-09-2011

A new study reports that a drug already approved by the US Food and Drug Administration for use in patients…

BiotechnologyGenzymeImmunologicalsMozobilPharmaceuticalPlerixaforRare diseasesResearchSanofi

PTC Therapeutics and Genzyme restructuring ataluren collaboration

04-09-2011

Privately-held PTC Therapeutics and fellow USA-based Genzyme, now part of French drug major Sanofi (Euronext:…

atalurenGenzymeLicensingPharmaceuticalPTC TherapeuticsRare diseasesSanofi

Shire says Fabry and Gaucher disease studies continue to support patient switches to Replagal and Vpriv

01-09-2011

Ireland-headquartered specialty drug firm Shire (LSE: SHP) reported positive data from several studies…

CerezymeFabrazymeGenzymePharmaceuticalRare diseasesReplagalResearchSanofiShireVpriv

Mixed Ph III results for Sanofi MS drug candidate Lemtrada; EMA to broaden review of Multaq

12-07-2011

French drug major Sanofi (Euronext: SAN) and its US biotech subsidiary Genzyme have announced mixed top-line…

AlemtuzumabBiotechnologyCardio-vascularEuropeGenzymeLemtradaMultaqPharmaceuticalRegulationResearchSanofi

Sanofi-Aventis net profit in 1st-qrt 2011 slumps 29%, battered by generics and low flu sales

29-04-2011

French drug major Sanofi-Aventis (Euronext: SAN) posted first-quarter 2011 results yesterday, showing…

BiotechnologyFinancialGenzymePharmaceuticalSanofi-Aventis

46 to 70 of 70 results

Back to top